Kyverna Therapeutics, Inc.
KYTXHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Kyverna Therapeutics, Inc. focuses on Biotechnology services and products. Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. With a market capitalization of $510.2M, it sits in small-cap territory. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.
Market Cap
$510.2M
Beta
1.99
P/E (TTM)
—
P/E (Fwd)
-2.69
EPS (TTM)
$-2.92
EPS (Fwd)
$-3.07
ROE
-87.2%
ROA
-44.5%
Cash
$199.4M
Total Debt
$33.0M
Free CF
-$107.7M
52W Change
101.2%
Annual Financials
Cash vs Debt
Where KYTX stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, KYTX finished 1.07% below its 150-day moving average ($8.44) and 0.71% below its 200-day moving average ($8.41). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is KYTX overbought or oversold?
At the September 2, 2026 close, KYTX's RSI(14) was 53.5, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $199.4M in cash comfortably exceeding the $33.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$107.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -87.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $5.7M (2021) to $0 (2025), a 100% decline worth watching.
A beta of 1.99 means KYTX is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, KYTX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing KYTX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.